Progress in the knowledge and treatment of advanced pancreatic cancer: From benchside to bedside

- Progress in the treatment of pancreatic cancer has been frustratingly slow over the past decades.
- Targeting the primary tumor alone is inadequate.
- Pancreatic cancer is notoriously resistant to chemotherapy mainly due to an abundant stroma which surrounds the tumor.
- New compound which target the tumor stroma: nab-paclitaxel in combination with gemcitabine.

Ever since a pivotal study in 1997 demonstrated superiority of gemcitabine over 5-FU, gemcitabine monotherapy has, until recently, comprised the standard of care in patients with advanced pancreatic cancer. However, the emerging recognition of the pancreatic cancer microenvironment, including the particularly abundant stroma, as playing a key role in disease progression and resistance to chemotherapy has marked somewhat of a paradigm shift in the way treatment of advanced pancreatic cancer is viewed, with these very same biological defenses conversely offering an Achilles heel with which to combat this aggressive disease. Recently, this approach was validated for the first time in a pivotal phase III trial in which patients received nab-paclitaxel, a stroma-targeted drug, with gemcitabine. Overall survival was significantly (p < 0.001) prolonged in the combination arm, compared with gemcitabine alone, and thus these convincing results pave the way forward for future treatment regimens that employ a multipronged approach, targeting not only the primary tumor but the surrounding microenvironment as well.